leadf
logo-loader
AIM:AGY

Allergy Therapeutics PLC

 Receive alerts
Market:
AIM
Market Cap:
£113.12 m
Price
17.75 GBX
Change
-2.07%
52 weeks high
21.50
52 weeks low
7.00
09.30

Director Interviews

In brief

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Allergy Therapeutics to top expectations despite coronavirus challenges
Allergy Therapeutics PLC -

Snapshot

  • Profitable allergy specialist developing new inoculations
  • Strong revenue growth in Europe
  • Long pipeline of new products under development
Open Deep dive

Latest news

Allergy Therapeutics broadens its collaboration with vaccine pair in a deal...

2 weeks, 3 days ago

Allergy Therapeutics earnings to exceed expectations after a strong year

on 15/7/20

Allergy Therapeutics allowed to hit the reset button on birch pollen phase...

on 9/7/20

Allergy Therapeutics says 2020 net profit will be well ahead of expectations

on 24/6/20

Allergy Therapeutics welcomes academic paper's endorsement of adjuvant...

on 22/4/20

Allergy Therapeutics hails "steady" first half performance; finnCap ups...

on 4/3/20

Allergy Therapeutics: Journal article flags up potential of peanut vaccine

on 29/1/20

Allergy Therapeutics sees sales grow in all countries

on 16/1/20

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Allergy Therapeutics PLC -
Allergy Therapeutics gets big forecast upgrade from finncap after trading update

The broker now expects profits to around £5m higher than its previous forecasts at £2.9m.

on 24/6/20

Watch

Allergy Therapeutics PLC - Allergy Therapeutics on the potential of peanut vaccine Director Interviews Allergy Therapeutics on the potential of peanut vaccine
on 3/3/20
Allergy Therapeutics PLC - Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues Director Interviews Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues
on 25/9/19
1562832810_UPDATE_JULY_11.jpg Director Interviews Benchmark Holdings identifies breakthrough to help Tilapia fight disease
on 11/7/19
1562830167_ALLERGY_JULY_11.jpg Director Interviews Allergy Therapeutics expects earnings to come in ahead of market expectations
on 11/7/19
View all